Combining Immunotherapies to Treat Liver Cancer
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with hepatocellular carcinoma.
Progress Against Cancer
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with hepatocellular carcinoma.
The FDA has approved a new therapeutic to treat adults with multiple myeloma whose cancer has progressed despite receiving at least two other treatments.
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients with advanced or metastatic breast cancer
The FDA has approved a molecularly targeted therapy for epithelioid sarcoma, the first treatment approved for this rare form of soft tissue sarcoma.
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More